Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide adjunctive therapy for myoclonic seizures in idiopathic generalized epilepsy
ACTRN12608000097347Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in idiopathic epilepsy (IGE) comparing Zonisamide adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Decrease of seizure frequency. Started Feb 2008; status: terminated.
02
Drugs
zonisamide
03
Conditions
idiopathic epilepsy (IGE)
Beyond the preview
Go deeper on ACTRN12608000097347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000097347.